David Hoang
Stock Analyst at Deutsche Bank
(2.02)
# 3,057
Out of 4,979 analysts
41
Total ratings
41.94%
Success rate
-4.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $17.60 | -31.82% | 8 | Aug 15, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $55 | $35.83 | +53.52% | 3 | Jul 10, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $25.39 | +37.85% | 5 | May 21, 2025 | |
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $28.45 | +82.78% | 2 | Mar 27, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $38.18 | +75.48% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $40.75 | +172.39% | 1 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $15.51 | +99.87% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $14.49 | +348.59% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $129.29 | +36.13% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $15.38 | -21.98% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $143.80 | +9.87% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.41 | +396.45% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.13 | +211.89% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.26 | +275.59% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $455.03 | -51.65% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $27.17 | +194.44% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $2.66 | +12.78% | 1 | Dec 7, 2022 |
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $17.60
Upside: -31.82%
Harmony Biosciences Holdings
Jul 10, 2025
Maintains: Buy
Price Target: $54 → $55
Current: $35.83
Upside: +53.52%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $25.39
Upside: +37.85%
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $28.45
Upside: +82.78%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $38.18
Upside: +75.48%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $40.75
Upside: +172.39%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $15.51
Upside: +99.87%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $14.49
Upside: +348.59%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $129.29
Upside: +36.13%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $15.38
Upside: -21.98%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $143.80
Upside: +9.87%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.41
Upside: +396.45%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.13
Upside: +211.89%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.26
Upside: +275.59%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $455.03
Upside: -51.65%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $27.17
Upside: +194.44%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $2.66
Upside: +12.78%